Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may have an effect on cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month period.


Clinical Trial Description

The core rationale of this study will be to prospectively investigate whether Vitamin B12, B6 and Folic Acid and the associated lowering of homocysteine levels will improve and /or protect cognitive functioning in a cohort of 120 first episode psychosis patients.

This is a randomized, double blind placebo controlled add on standard therapy trial with vitamin B12, B6 and folic acid, in young patients between 15-25 presenting to ORYGEN Youth Health with a first psychotic episode . Vitamins (B12 , B6 and Folate) will be compared with placebo added to standard treatment for a period of 12 weeks in a double blind fashion. Primary outcome measures will be psychopathology and cognition (CogState and MATRICS). Secondary outcome measures will be tolerability and safety measures (drop-out rates, general side effect scale (UKU).

Patients who give informed consent will be randomised to receive treatment with vitamin (5 mg folic acid, 0.4 mg B12, and 50 mg B6) daily or placebo for 12 weeks.

Patients will be randomised by a dynamic randomisation method called minimization which allocates patients to treatment group by checking the allocation of similar patients already randomised, and allocating the next treatment group "live" to best balance the treatment groups across all stratification variables. The minimization will be carried out by the NHMRC clinical trials centre in Sydney , and the patient will be randomized to either placebo or vitamin. Each patient will collect their tablets from the clinical trials pharmacy. The Clinical Trials Pharmacy will dispense either vitamin or placebo. All study personnel and participants will be blinded to treatment assignment for the duration of the study. To enhance the quality of measurement (and increase the power of the study by avoiding dilution of effect) adherence to medication will be measured electronically with electronic pill caps (Medication Event Monitoring System VI, ARRDEX Ltd). This will allow us to assess actual pharmacological exposure in an objective manner. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00202280
Study type Interventional
Source Melbourne Health
Contact
Status Completed
Phase Phase 2/Phase 3
Start date September 2004
Completion date June 2009

See also
  Status Clinical Trial Phase
Recruiting NCT04298450 - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention N/A
Completed NCT01026584 - Efficacy and Safety of Aripiprazole in First Episode Psychosis Phase 4
Completed NCT03983421 - Feasibility of an Early Detection Program for Early Psychosis on a College Campus
Recruiting NCT04046497 - Artificial Intelligence to Measure Adherence to Oral Medication Phase 4
Withdrawn NCT04369677 - Thermoregulation Among Individuals With First-episode Psychosis
Completed NCT03568500 - A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic Phase 4
Completed NCT03102151 - Reducing the Duration of Untreated Psychosis
Completed NCT00916461 - Role of Minocycline in First Episode Psychosis Phase 1/Phase 2
Recruiting NCT05310838 - Optimizing Engagement in Services for First-Episode Psychosis N/A
Completed NCT03501160 - Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective
Recruiting NCT03196128 - Early Intervention Psychosis Communication and Engagement Trial N/A
Recruiting NCT04005378 - Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs Phase 4
Recruiting NCT03919760 - Early Psychosis Intervention - Spreading Evidence-based Treatment
Completed NCT03409393 - Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis N/A
Completed NCT01753284 - First Episode Psychosis and Pathway to Care in Nordland
Completed NCT01157585 - Efficacy and Safety of Paliperidone ER in First Episode Psychosis Phase 4
Completed NCT05737966 - Evaluation of Case Management for First Episode Psychosis Using the PEPsy-CM Checklist
Recruiting NCT04021719 - OnTrackNY's Learning Healthcare System
Recruiting NCT04889911 - Pilot RCT of Self-stigma Treatment for First Episode Psychosis N/A
Recruiting NCT04853485 - Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes N/A